Clinical Trial

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, open, multicenter phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection versus gemcitabine in combination with docetaxel in patients with osteosarcoma who have at least second-line treatment failure.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-17.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-06
Trial Details
NCT Number NCT06935409
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Osteosarcoma
Enrollment 117 participants
Start Date 2025-04-25
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09